Switch theme
Sign up to access all valuation multiples
Farmacosmo SpA is a wellness e-commerce company active in the Health, Pharma, and Wellness industry, authorized by the Italian Ministry of Health to sell pharmaceutical products online. In particular, the company offers parapharmaceutical products, vitamins and food supplements, dietetic products, medical devices, cosmetic products, personal hygiene products, hair care products, dental care products, skincare products, perfumes, home and baby items.
2013
n/a
LTM Revenue $70.6M
LTM EBITDA $0.6M
$27.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Farmacosmo has a last 12-month revenue (LTM) of $70.6M and a last 12-month EBITDA of $0.6M.
In the most recent fiscal year, Farmacosmo achieved revenue of $80.4M and an EBITDA of -$0.5M.
Farmacosmo expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Farmacosmo valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $70.6M | XXX | $80.4M | XXX | XXX | XXX |
| Gross Profit | $37.5M | XXX | $17.9M | XXX | XXX | XXX |
| Gross Margin | 53% | XXX | 22% | XXX | XXX | XXX |
| EBITDA | $0.6M | XXX | -$0.5M | XXX | XXX | XXX |
| EBITDA Margin | 1% | XXX | -1% | XXX | XXX | XXX |
| EBIT | -$2.2M | XXX | -$3.4M | XXX | XXX | XXX |
| EBIT Margin | -3% | XXX | -4% | XXX | XXX | XXX |
| Net Profit | -$3.2M | XXX | -$3.6M | XXX | XXX | XXX |
| Net Margin | -5% | XXX | -5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Farmacosmo's stock price is EUR 1 (or $1).
Farmacosmo has current market cap of EUR 22.9M (or $25.7M), and EV of EUR 24.8M (or $27.9M).
See Farmacosmo trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $27.9M | $25.7M | XXX | XXX | XXX | XXX | $-0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Farmacosmo has market cap of $25.7M and EV of $27.9M.
Farmacosmo's trades at 0.3x EV/Revenue multiple, and -61.2x EV/EBITDA.
Equity research analysts estimate Farmacosmo's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Farmacosmo has a P/E ratio of -8.1x.
See valuation multiples for Farmacosmo and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $25.7M | XXX | $25.7M | XXX | XXX | XXX |
| EV (current) | $27.9M | XXX | $27.9M | XXX | XXX | XXX |
| EV/Revenue | 0.4x | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBITDA | 44.2x | XXX | -61.2x | XXX | XXX | XXX |
| EV/EBIT | -12.4x | XXX | -8.2x | XXX | XXX | XXX |
| EV/Gross Profit | 0.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -8.1x | XXX | -7.1x | XXX | XXX | XXX |
| EV/FCF | -24.0x | XXX | -3.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFarmacosmo's last 12 month revenue growth is 2%
Farmacosmo's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Farmacosmo's rule of 40 is 2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Farmacosmo's rule of X is 6% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Farmacosmo and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | -3% | XXX | XXX | XXX |
| EBITDA Margin | 1% | XXX | -1% | XXX | XXX | XXX |
| EBITDA Growth | 90% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 2% | XXX | 1% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 6% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 26% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Farmacosmo acquired XXX companies to date.
Last acquisition by Farmacosmo was XXXXXXXX, XXXXX XXXXX XXXXXX . Farmacosmo acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Farmacosmo founded? | Farmacosmo was founded in 2013. |
| Where is Farmacosmo headquartered? | Farmacosmo is headquartered in Italy. |
| Is Farmacosmo publicy listed? | Yes, Farmacosmo is a public company listed on MIL. |
| What is the stock symbol of Farmacosmo? | Farmacosmo trades under COSMO ticker. |
| When did Farmacosmo go public? | Farmacosmo went public in 2022. |
| Who are competitors of Farmacosmo? | Similar companies to Farmacosmo include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of Farmacosmo? | Farmacosmo's current market cap is $25.7M |
| What is the current revenue of Farmacosmo? | Farmacosmo's last 12 months revenue is $70.6M. |
| What is the current revenue growth of Farmacosmo? | Farmacosmo revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Farmacosmo? | Current revenue multiple of Farmacosmo is 0.4x. |
| Is Farmacosmo profitable? | Yes, Farmacosmo is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Farmacosmo? | Farmacosmo's last 12 months EBITDA is $0.6M. |
| What is Farmacosmo's EBITDA margin? | Farmacosmo's last 12 months EBITDA margin is 1%. |
| What is the current EV/EBITDA multiple of Farmacosmo? | Current EBITDA multiple of Farmacosmo is 44.2x. |
| What is the current FCF of Farmacosmo? | Farmacosmo's last 12 months FCF is -$1.2M. |
| What is Farmacosmo's FCF margin? | Farmacosmo's last 12 months FCF margin is -2%. |
| What is the current EV/FCF multiple of Farmacosmo? | Current FCF multiple of Farmacosmo is -24.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
